![Mark Lewis: Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!](https://oncodaily.com/pub/uploads/2024/02/GGQ4kKEaAAAYhqk-1280x664.jpeg)
Photo taken from: Mark Lewis/X
Feb 14, 2024, 18:02
Mark Lewis: Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!
Mark Lewis shared on X:
“Seems relevant to resurface Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!”
Source: Mark Lewis/X
Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.